Translation potential of innovative therapies in urothelium cancer

Poster Session 01

Friday 20 March
09:00 - 10:30

Location: Orange Area, eURO Auditorium 2
 Chairs: A. Necchi, Milan (IT)
To be confirmed
T. Todenhöfer, Tübingen (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 1

VAR2-armed CAR T-cells as an immunotherapeutic strategy for bladder cancer

By: Oo H.Z., Khazamipour N., Ardekani G., Roberts M., Al Nakouzi N., Gustavsson T., Fazli L., Salanti A., Black P., Daugaard M.

1Vancouver Prostate Centre, University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 2Centre for Medical Parasitology, University of Copenhagen, Dept. of Immunology and Microbiology, Copenhagen, Denmark

* 2

The supplementary GM-CSF to neoadjuvant gemcitabine-cisplatin systemic chemotherapy plus PD-L1 blockade decrease local tumor recurrence of urothelial carcinoma after surgery via suppression of MDSCs in blood and tumor microenvironment

By: Miyake M., Hori S., Nishimura N., Owari T., Itami Y., Nakai Y., Tanaka N., Fujimoto K.
Nara Medical University, Dept. of Urology, Nara, Japan

3

Targeting myeloid-derived suppressor cells (MDSCs) with immune checkpoint inhibitors for treating cisplatin-resistant bladder cancer

Osaka City University Graduate School of Medicine, Dept. of urology, Osaka, Japan

4

Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses


1Rouen University Hospital, Dept. of Urology, Rouen, France, 2Paoli-Calmette Institute, Dept. of Oncology, Marseille, France, 3Leon Berard Cancer Center, Dept. of Oncology, Lyon, France, 4Rangueil University Hospital, Dept. of Urology, Toulouse, France,
5 Cis-platinum induces immunity evasion demonstrated by PD-L1 expression in bladder cancer cells

By: Hwang T.¹, Chen P.², Tsai T.¹, Yang S.², Chen H.¹, Lin Y.¹, Chou K.¹, Lin J.²

¹Shin Kong WHS Memorial Hospital, Dept. of Urology, Taipei, Taiwan, ²Shin Kong WHS Memorial Hospital, Dept. of Central Laboratory, Taipei, Taiwan

6 Semaphorin 3C knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes in bladder cancer

By: Takeuchi A., Shiota M., Inokuchi J., Eto M.
Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan

7 Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization and causes bladder cancer with p53 dysfunction

By: Kobatake K.¹, Ikeda K.¹, Nakata Y.², Yamasaki N.², Hayashi T.¹, Sentani K.³, Yasui W.³, Kaminuma O.², Horie S.⁴, Black P.C.⁵, Matsubara A.¹, Honda H.⁶
¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Research Institute for Radiation Biology and Medicine, Hiroshima University, Dept. of Disease Model, Hiroshima, Japan, ³Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan, ⁴Juntendo University, Dept. of Urology, Tokyo, Japan, ⁵University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁶Institute of Laboratory animals, Tokyo Women's Medical University, Dept. of Human Disease Model, Tokyo, Japan

8 An internal cross-linked polymeric nanoparticle with dual sensitivity for combination therapy of muscle-invasive bladder cancer

By: Zhu G.C.¹, Qin H.X.¹, Zhao X.Z.¹, Xu L.F.¹, Chen W.¹, Cao W.M.¹, Wang K.K.², Guo H.Q.¹
¹Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, ²Nantong University, Dept. of Pharmacy, Nantong, China

9 Effects of miR-30a-3p on autophagy and invasion in bladder cancer cell

By: Chou K-Y.¹, Chen P-C.², Ciou P-C.², Tsai T-F.¹, Chen H-E.¹, Lin Y-C.¹, Lin J-F.², Hwang T.I.¹
**Scientific Programme - EAU20 Amsterdam**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Vorinostat and Ixazomib cause bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress</td>
<td>Sato A., Asano T., Okubo K.</td>
<td>National Defense Medical College, Dept. of Urology, Tokorozawa, Japan</td>
</tr>
<tr>
<td>11</td>
<td>Simvastatin augments anticancer activity of romidepsin in bladder cancer cells by causing AMP-activated protein kinase activation and histone acetylation</td>
<td>Okubo K., Asano T., Sato A.</td>
<td>National Defense Medical College, Dept. of Urology, Tokorozawa, Japan</td>
</tr>
<tr>
<td>12</td>
<td>Ritonavir, a potent inhibitor of CYP3A4, enhances the anticancer effects of panobinostat in bladder cancer cells</td>
<td>Sato A., Asano T., Okubo K.</td>
<td>National Defense Medical College, Dept. of Urology, Tokorozawa, Japan</td>
</tr>
<tr>
<td>10:11 - 10:18</td>
<td>Summary</td>
<td>To be confirmed</td>
<td></td>
</tr>
</tbody>
</table>